Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5093151 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO5093151 | EXPERIMENTAL | - |
| Part A | EXPERIMENTAL | Participants will receive up to 3 multiple ascending dose levels with the starting dose of 0.1% RO5093151 (topical ocular instillation) and sequentially 0.5% and 1% RO5093151 doses or placebo (3:1, active:placebo) twice a day (BID) on Day 1 and once a day (QD) for 6 days. |
| Part B | EXPERIMENTAL | Participants will receive highest feasible dose (HFD) or maximum tolerated dose (MTD) of RO5093151 from Part A or 0.005% latanoprost (topical ocular instillation) once daily for 7 days. |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo to RO5093151 |
| RO5093151 | DRUG | oral doses twice daily for up to 28 days |
| Latanoprost | DRUG | Latanoprost is a ophthalmic solution, available in dose strength as 0.005%. |
Inclusion Criteria: * Adult patients, at least 21 years of age, inclusive * Diagnosis of ocular hypertension or primary open angle glaucoma in at least one eye * Able to participate and willing to give informed consent Exclusion Criteria: * Presence of extreme narrow angle with complete or partia...
RO5093151 is an investigational small molecule developed by Roche Holding AG. It has been studied in clinical trials for non-alcoholic fatty liver disease (NAFLD) and for ocular hypertension or open-angle glaucoma. It is not described as an approved medicine and remains in clinical development.
RO5093151 has been studied in trials for non-alcoholic fatty liver disease, including fatty liver, and for ocular hypertension and open-angle glaucoma. These studies evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics. The drug is investigational and has not been described as approved for any indication.
RO5093151 is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored the clinical studies of the compound in patients with non-alcoholic fatty liver disease and in patients with ocular hypertension or open-angle glaucoma.
RO5093151 is in Phase 1 development. One completed Phase 1 study enrolled 82 patients with non-alcoholic fatty liver disease, and a completed Phase 2 study enrolled 31 patients with ocular hypertension or open-angle glaucoma. The compound is investigational and is not described as FDA approved.
RO5093151 has been evaluated in completed trials including NCT01277094, a Phase 1 study in non-alcoholic fatty liver disease with 82 patients, NCT02622334, a Phase 1 study in primary open-angle glaucoma or ocular hypertension with 45 patients, and NCT01493271, a Phase 2 study in ocular hypertension or open-angle glaucoma with 31 patients.
RO5093151 is a small molecule, but its specific molecular target is not identified in the available trial information. Its clinical studies assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with non-alcoholic fatty liver disease and in patients with ocular hypertension or open-angle glaucoma.